Table III.
Baseline characteristics of the study population used for EGFR validation experiment.
| Characteristics | Control (n=342) | CAD patients (n=342) | P-value |
|---|---|---|---|
| Age, (years) | 41.51±0.26 | 41.51±0.26 | 1 |
| Males, n (%) | 240 (70.2) | 240 (70.2) | 1 |
| Females, n (%) | 102 (29.8) | 102 (29.8) | |
| BMI (kg\m2) | 26.07±0.26 | 25.84±0.22 | 0.481 |
| Waist Circumference (cm) | 91.68±0.65 | 87.94±0.55 | <0.001 |
| SBP (mmHg) | 122.24±0.89 | 117.76±0.82 | <0.001 |
| DBP (mmHg) | 81.11±0.58 | 77.75±0.47 | <0.001 |
| FBS (mg/dl) | 94.31±1.92 | 114.70±3.41 | <0.001 |
| Age at onset (years) | 40.88±0.297 | ||
| Stable angina, n (%) | 182 (53.2) | ||
| Myocardial infarction, n (%) | 160 (46.8) | ||
| Number of diseased vessels, n (%) | |||
| 0 | 36 (10.5) | ||
| 1 | 93 (27.2) | ||
| 2 | 88 (25.7) | ||
| 3 | 125 (36.5) | ||
| Current Smoking, n (%) | 62 (18.3) | 148 (43.3) | <0.001 |
| Alcohol habit, n (%) | 68 (20.1) | 89 (26) | 0.065 |
| Hypertension, n (%) | 38 (11.3) | 127 (37.1) | <0.001 |
| Diabetes, n (%) | 48 (14.2) | 118 (34.7) | <0.001 |
| Total cholesterol (mg/dl) | 171.58±2.03 | 152.36±2.99 | <0.001 |
| Triglyceride (mg/dl) | 154.95±5.42 | 170.71±4.69 | 0.03 |
| HDL-c (mg/dl) | 40.11±0.498 | 34.76±0.596 | <0.001 |
| LDL-c (mg/dl) | 101.28±1.65 | 83.88±2.72 | <0.001 |
| Metabolic syndrome, n (%) | 90 (26.4) | 153 (44.7) | <0.001 |
| Statins, n (%) | – | 226 (68.5) | – |
| EGFR (pg/ml) | 154.11±2.68 | 161.93±2.54 | 0.007 |
Continuous variables are presented as mean ± standard error and categorical variable as frequencies. CAD, coronary artery disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar; HDL-c, high density lipid cholesterol; LDL-c, low density lipid cholesterol; EGFR, epidermal growth factor receptor.